<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657176</url>
  </required_header>
  <id_info>
    <org_study_id>252-KOA-0701</org_study_id>
    <nct_id>NCT00657176</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, single-center, dose-escalation study in patients with
      advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned
      for the study. In this study, OPB-31121's potential for toxic effects will be evaluated in
      patients with advanced solid tumors to evaluate the recommended dose for use in subsequent
      studies. The pharmacokinetics and antitumor effect of the compound will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and dose-limiting toxicity</measure>
    <time_frame>Duration of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effect</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-31121</intervention_name>
    <description>100mg tablet
oral administration, Qd</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Histologically confirmed solid tumor refractory to standard therapy or for which there
             is no standard therapy

          2. Age: more than 19 years

          3. ECOG performance status: less than 2

          4. Life expectancy of longer than 3 months

          5. Adequate vital organ function as follows:

               -  Bone marrow function

                    -  neutrophils: more than 1,500 per microliter

                    -  platelets: more than 75,000 per microliter

                    -  hemoglobin: more than 10.0g per deciliter

               -  Hepatic function

                    -  AST and ALT: less than 2.5 x institutional upper limit normal

                    -  serum total bilirubin: less than 2.5 x institutional ULN

               -  Renal function

                    -  Serum creatinine: less than 1.5 x institutional ULN

          6. Capable of swallowing OPB-31121 tablets

          7. Ability to understand and willingness to sign written informed consent document for
             participation in the trial and for analysis of genotypes CYP2C9 and NAT2

          8. No chemotherapy, radiotherapy, surgery, or immunotherapy within 4 weeks prior to study
             entry and recovered from any prior toxicity

        Exclusion criteria:

          1. Symptomatic CNS metastasis

          2. Uncontrolled concurrent illness, including active infection, heart failure, angina
             pectoris, and cardiac arrhythmia

          3. Psychiatric illness that would limit compliance with study requirements

          4. Pregnant or breast-feeding women and women of childbearing potential who cannot or
             will not use effective contraceptive measures

          5. Administration of another investigational agent within 6 months prior to study entry

          6. Use of CYP3A4 and CYP2C9 inducers, inhibitors, or substrates, and CYP2B6, CYP2C8 and
             CYP2D6 substrates

          7. Hyperlipidemia:

             Total cholesterol:more than 300 milligram per deciliter or Triglycerides:

             more than 2.5 x institutional ULN

          8. Abnormal thyroid function: Hypothyroidism or hyperthyroidism of grade 2 or higher
             (graded according to the NCI-CTCAE)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yung-Jue Bang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Medical Oncology, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yung-Jue Bang, PhD</last_name>
    <phone>82-2-2072-2390</phone>
    <email>bangyj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanna Lee, Bachelor</last_name>
    <phone>82-2-2072-0603</phone>
    <email>life1025@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Lee, Bachelor</last_name>
      <phone>+82-2-2072-0603</phone>
      <email>life1025@naver.com</email>
    </contact>
    <investigator>
      <last_name>Yung-Jue Bang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>April 17, 2008</last_update_submitted>
  <last_update_submitted_qc>April 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sol Han / Clinical Research Associate</name_title>
    <organization>Clinical Research Team</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

